RxDoctor Payments Data

Anita Kunwar, MD

Internal Medicine · Washington, DCNPI 1053746578

Payments from drug & device makers

$976in general payments, 2019–2025

Across 51 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$268
  • Exact Sciences$179
  • Lilly USA, LLC$142
  • Novo Nordisk$102
  • GSK$59
  • Astellas Pharma US Inc$53
  • plus $172 from 7 others

What the payments were for

  • Food & beverage$976100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$976 in reported general payments places this provider in the 75th percentile of 645 internal medicine providers in District of Columbia.

See all internal medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$70,720
Medicare patients
241
Services billed
625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$62,115
OzempicSemaglutide61$61,661
XifaxanRifaximin13$45,430
JardianceEmpagliflozin47$40,294
LinzessLinaclotide43$30,205
FarxigaDapagliflozin Propanediol39$28,255
RybelsusSemaglutide23$24,193
MounjaroTirzepatide19$23,849
MyrbetriqMirabegron38$21,377
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,483
XareltoRivaroxaban21$13,841
Atorvastatin Calcium400$6,173
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$3,667
Amlodipine Besylate328$3,301
Metoprolol Succinate178$3,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$102$85,85484 claims
PfizerEliquis$36$62,11553 claims
AbbVieLinzess, Synthroid$268$31,47268 claims
AstraZenecaFarxiga$17$28,25539 claims
Lilly USA, LLCMounjaro$142$23,84919 claims
Astellas Pharma US IncMyrbetriq$53$21,37738 claims
GSKTrelegy Ellipta$59$14,48317 claims
Johnson & JohnsonXarelto$23$13,84121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 645 internal medicine providers in District of Columbia.

Other internal medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →